OBJECTIVE: To analyse the mid region of plasma N-terminal pro-atrial natriuretic peptide (MR-proANP) levels in patients with lower respiratory tract infections to evaluate its prognostic use for the severity of disease and outcome. DESIGN: Prospective observational study. Setting. Emergency department of a university hospital. SUBJECTS: A total of 545 consecutive patients with lower respiratory tract infections and 50 healthy controls. Interventions. MR-proANP was measured in serum from all patients using a new sandwich immunoassay. RESULTS: MR-proANP levels (median [IQR], in pmol L(-1)) were significantly higher in patients with lower respiratory tract infections when compared with controls (138.0 [74.1-279.0] vs. 72.7 [62.5-89.5], P < 0.001), with highest levels in patients with community-acquired pneumonia (CAP). MR-proANP, but not C-reactive protein (CRP) levels, gradually increased with increasing severity of CAP, classified according to the pneumonia severity index (PSI) score (P < 0.001). On admission, MR-proANP levels were significantly higher in nonsurvivors when compared with survivors (293.0 [154.0-633.0] vs. 129.0 [71.4-255.0], P < 0.001). In a receiver operating characteristic (ROC) analysis for the prediction of survival of patients with CAP the area under the ROC curve (AUC) for MR-proANP was 0.69, similar when compared with the PSI (AUC 0.74, P = 0.31), and better when compared with other biomarkers, i.e. procalcitonin (AUC 0.57, P = 0.08), CRP (AUC 0.52, P = 0.02), and leucocyte count (AUC 0.56, P = 0.07). CONCLUSIONS: MR-proANP levels are increased in lower respiratory tract infections, especially in CAP. Together with other clinical, radiographic and laboratory findings, MR-proANP levels might be helpful for the risk stratification in CAP.
OBJECTIVE: To analyse the mid region of plasma N-terminal pro-atrial natriuretic peptide (MR-proANP) levels in patients with lower respiratory tract infections to evaluate its prognostic use for the severity of disease and outcome. DESIGN: Prospective observational study. Setting. Emergency department of a university hospital. SUBJECTS: A total of 545 consecutive patients with lower respiratory tract infections and 50 healthy controls. Interventions. MR-proANP was measured in serum from all patients using a new sandwich immunoassay. RESULTS:MR-proANP levels (median [IQR], in pmol L(-1)) were significantly higher in patients with lower respiratory tract infections when compared with controls (138.0 [74.1-279.0] vs. 72.7 [62.5-89.5], P < 0.001), with highest levels in patients with community-acquired pneumonia (CAP). MR-proANP, but not C-reactive protein (CRP) levels, gradually increased with increasing severity of CAP, classified according to the pneumonia severity index (PSI) score (P < 0.001). On admission, MR-proANP levels were significantly higher in nonsurvivors when compared with survivors (293.0 [154.0-633.0] vs. 129.0 [71.4-255.0], P < 0.001). In a receiver operating characteristic (ROC) analysis for the prediction of survival of patients with CAP the area under the ROC curve (AUC) for MR-proANP was 0.69, similar when compared with the PSI (AUC 0.74, P = 0.31), and better when compared with other biomarkers, i.e. procalcitonin (AUC 0.57, P = 0.08), CRP (AUC 0.52, P = 0.02), and leucocyte count (AUC 0.56, P = 0.07). CONCLUSIONS:MR-proANP levels are increased in lower respiratory tract infections, especially in CAP. Together with other clinical, radiographic and laboratory findings, MR-proANP levels might be helpful for the risk stratification in CAP.
Authors: A Lacoma; N Rodríguez; C Prat; J Ruiz-Manzano; F Andreo; A Ramírez; A Bas; M Pérez; V Ausina; J Domínguez Journal: Eur J Clin Microbiol Infect Dis Date: 2011-08-26 Impact factor: 3.267
Authors: Katherine Adams; Mark W Tenforde; Shreya Chodisetty; Benjamin Lee; Eric J Chow; Wesley H Self; Manish M Patel Journal: Hum Vaccin Immunother Date: 2021-11-10 Impact factor: 3.452
Authors: Renato Seligman; Jana Papassotiriou; Nils G Morgenthaler; Michael Meisner; Paulo J Z Teixeira Journal: Intensive Care Med Date: 2008-06-04 Impact factor: 17.440
Authors: Philipp Schuetz; Pierre Hausfater; Devendra Amin; Sebastian Haubitz; Lukas Fässler; Eva Grolimund; Alexander Kutz; Ursula Schild; Zeljka Caldara; Katharina Regez; Andriy Zhydkov; Timo Kahles; Krassen Nedeltchev; Stefanie von Felten; Sabina De Geest; Antoinette Conca; Petra Schäfer-Keller; Andreas Huber; Mario Bargetzi; Ulrich Buergi; Gabrielle Sauvin; Pasqualina Perrig-Chiello; Barbara Reutlinger; Beat Mueller Journal: BMC Emerg Med Date: 2013-07-04
Authors: Philipp Schuetz; Marcel Wolbers; Mirjam Christ-Crain; Robert Thomann; Claudine Falconnier; Isabelle Widmer; Stefanie Neidert; Thomas Fricker; Claudine Blum; Ursula Schild; Nils G Morgenthaler; Ronald Schoenenberger; Christoph Henzen; Thomas Bregenzer; Claus Hoess; Martin Krause; Heiner C Bucher; Werner Zimmerli; Beat Mueller Journal: Crit Care Date: 2010-06-08 Impact factor: 9.097
Authors: Philipp Schuetz; Mirjam Christ-Crain; Marcel Wolbers; Ursula Schild; Robert Thomann; Claudine Falconnier; Isabelle Widmer; Stefanie Neidert; Claudine A Blum; Ronald Schönenberger; Christoph Henzen; Thomas Bregenzer; Claus Hoess; Martin Krause; Heiner C Bucher; Werner Zimmerli; Beat Müller Journal: BMC Health Serv Res Date: 2007-07-05 Impact factor: 2.655
Authors: Philipp Schuetz; Daiana Stolz; Beat Mueller; Nils G Morgenthaler; Joachim Struck; Christian Mueller; Roland Bingisser; Michael Tamm; Mirjam Christ-Crain Journal: BMC Infect Dis Date: 2008-02-28 Impact factor: 3.090